- Braxia Scientific enters new chapter as it begins operations under its new symbol “CSE: BRAX” and renames its growing network of leading clinics to Braxia Health, which includes the Canadian Center of Excellence for Rapid Treatment established in 2018.
- Only clinic in Canada previously involved in a pivotal randomized controlled trial for regulatory approval of psilocybin for the treatment of adults with depression.
- Led by Dr. Roger mcintyre, the top-rated depression expert since 2010 according to Expertscape, Braxia Health has the largest clinical research footprint in ketamine and psychedelic research in the world, providing the fastest path to the development of its IP compatible formulations and its IP administration methods.
- First community center in Canada to specialize in rapid-acting treatments for patients with treatment-resistant major depressive disorder and bipolar disorder.
- First Ontario Center approved by the College of Physicians and Surgeons of Ontario as part of the off-hospital program to perform IV ketamine treatment for depression.
- Over 3000 intravenous ketamine infusions and 345 intranasal and sublingual ketamine treatments administered to date in Canada.
- Focused on robust expansion everywhere Canada, the United States and Europe through strategic acquisitions and organic growth of existing patient services.
TORONTO, May 5, 2021 / PRNewswire / – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (FWB: 496) (OTCQB: SHRMF), is pleased to announce the rebranding of its growing network of research and treatment clinics to Braxia Health. The company also presented an update on its plan to expand its research, treatments and clinical footprint to seize significant opportunities in the multi-billion dollar North American mental health market. In addition, Braxia Scientific started its activities under its new symbol “CSE: BRAX”.
“Since the establishment of the first Braxia Health clinic in 2018, we have built an innovative and disruptive healthcare company with the world’s largest research footprint for the emerging psychedelics industry,” said Dr. Roger S. McIntyre, CEO of Braxia Scientific and President of Braxia Health. “In addition to providing clinical care with innovative treatments to patients with depression and other mental disorders, Braxia Health is an international leader in clinical research involving ketamine, psychedelic derivatives and other fast-acting treatments. A group of mental health clinics setting the standard of care through peer-reviewed industry protocols in an underserved market with significant growth opportunities. “
Braxia Health, the first of its kind in Canada, is a network of multidisciplinary outpatient clinical research treatment centers specializing in providing breakthrough, rapid-acting treatments for depression, such as intravenous ketamine and intranasal esketamine, which help patients with several treatment-resistant conditions such as as major depressive disorder or bipolar disorder. To date, the Company has launched 4 clinics in Canada and seeks to add additional clinics in 2021 in North America and Europe.
Ketamine and Esketamine Work
Ketamine and esketamine are the first fast-acting antidepressants that have been shown to significantly improve depressive symptoms within 24 hours. Both treatments represent the first treatments for depression that are mechanically different from antidepressants available for 70 years. In addition to being very effective, they have been shown to provide rapid symptom relief, especially in people who have not benefited from conventional antidepressant approaches. In addition, the evidence now indicates that ketamine and esketamine are effective in people with depression and suicidality.
About Braxia Scientific Corp.
Braxia Scientific is a research-driven medical solutions company that aims to reduce the burden of illnesses related to brain-related mental disorders such as major depressive disorder, among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatments for mental health disorders and (Braxia Health) and (ii) research activities related to the discovery and commercialization of new drugs and methods of administration. The company is developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community clinics providing treatment to Mississauga, Toronto, Ottawa, and Montreal.
ON BEHALF OF THE BOARD
“Dr. Roger S. McIntyre“
Dr. Roger S. McIntyre
Chairman and CEO
FOR FURTHER INFORMATION PLEASE CONTACT: Braxia Scientific Corp. (416) 762-2138
E-mail: [email protected]
Media: [email protected], 416 822-2288
The CSE has not reviewed and accepts no responsibility for the accuracy or adequacy of this release.
Cautionary Statement Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”.
Forward-looking statements include statements about the intended promise of ketamine and esketamine treatments for depression, and about the potential of ketamine to treat other emerging psychiatric disorders, in order for the company to be a leader in this area and for the company’s ability to develop its clinical networks.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to differ materially from any future results, events or developments expressed or implied by such statements. prospective. These risks and uncertainties include, among others, the inability of ketamine to provide the expected health benefits and unintended side effects, dependence on obtaining and maintaining regulatory approvals, including acquisition and renewal federal, provincial, municipal, local or other licenses and participation in activities. which could later be found to be illegal under national or international law.
These factors should be carefully considered and readers are cautioned not to place undue reliance on these forward-looking statements.
Although the Company has attempted to identify material risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results differ from those anticipated, estimated or expected. Additional information identifying the risks and uncertainties that could affect the financial results is contained in the documents filed by the Company with the Canadian securities regulators, including the amended and restated registration statement dated April 15, 2021, available on www.sedar.com. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.
SOURCE Braxia Scientific Corp.